Regulation FD Disclosure.
Exhibit 99.1 attached hereto is the slide presentation used by Jane Davies, M.D., when presenting data from our double and triple cystic fibrosis transmembrane
conductance regulator (CFTR) modulator combination studies on Tuesday August 6, 2019, at the 13
Australasian Cystic Fibrosis Conference in Perth, Australia. Dr. Davies is an
investigator for the CFTR modulator combination clinical trials in cystic fibrosis patients conducted by Proteostasis Therapeutics, Inc. (the Company). The presentation will be available through the Companys website.
The furnishing of the attached presentation slides is not an admission as to the materiality of any information therein. The information contained in the
presentation slides is summary information that is intended to be considered in the context of more complete information included in the Companys filings with the U.S. Securities and Exchange Commission, or the SEC, and other public
announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time
as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.
The information in this Item 7.01 of this Current Report on Form
and Exhibit 99.1 attached hereto is intended
to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the presentation slides attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC
made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.